Literature DB >> 17542460

Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity program.

Susan J Klein1, Lester N Wright, Guthrie S Birkhead, Benjamin A Mojica, Linda C Klopf, Laurence A Klein, Ellen L Tanner, Ira S Feldman, Edward J Fraley.   

Abstract

This article describes the development of a statewide program providing continuity of hepatitis C virus (HCV) treatment to prisoners upon release to the community. We discussed length of stay as a barrier to treatment with key collaborators; developed protocols, a referral process, and forms; mobilized staff; recruited heath-care facilities to accept referrals; and provided short-term access to HCV medications for inmates upon release. The Hepatitis C Continuity Program, including 70 prisons and 21 health-care facilities, is a resource for as many as 130 inmates eligible to start treatment annually. Health-care facilities provide fairly convenient access to 87.1% of releasees, and 100% offer integrated HCV-human immunodeficiency virus/acquired immunodeficiency syndrome care. As of March 2006, 24 inmates had been enrolled. The program was replicated in the New York City Rikers Island jail. The program is operational statewide, referrals sometimes require priority attention, and data collection and other details are still being addressed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542460      PMCID: PMC1831802          DOI: 10.1177/00333549071220S216

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  23 in total

1.  Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.

Authors:  Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

2.  Hepatitis C in state correctional facilities.

Authors:  A Spaulding; C Greene; K Davidson; M Schneidermann; J Rich
Journal:  Prev Med       Date:  1999-01       Impact factor: 4.018

Review 3.  Therapy of hepatitis C: cost-effectiveness analysis.

Authors:  R S Koff
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

4.  Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C.

Authors:  W G Bennett; S G Pauker; G L Davis; J B Wong
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 5.  Correctional health care: a public health opportunity.

Authors:  J B Glaser; R B Greifinger
Journal:  Ann Intern Med       Date:  1993-01-15       Impact factor: 25.391

6.  The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C.

Authors:  A Shiell; A Briggs; G C Farrell
Journal:  Med J Aust       Date:  1994-03-07       Impact factor: 7.738

7.  Opportunities to address the hepatitis C epidemic in the correctional setting.

Authors:  Amy E Boutwell; Scott A Allen; Josiah D Rich
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

8.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-16

9.  Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?

Authors:  Richard K Sterling; Charlotte M Hofmann; Velimir A Luketic; Arun J Sanyal; Melissa J Contos; A Scott Mills; Mitchell L Shiffman
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

10.  Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.

Authors:  G M Dusheiko; J A Roberts
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  11 in total

1.  Integrating viral hepatitis prevention into public health programs serving people at high risk for infection: good public health.

Authors:  Joanna Buffington; T Stephen Jones
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

2.  A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.

Authors:  John T Nguyen; Josiah D Rich; Bradley W Brockmann; Fred Vohr; Anne Spaulding; Brian T Montague
Journal:  J Urban Health       Date:  2015-08       Impact factor: 3.671

3.  Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system.

Authors:  Danica E Kuncio; E Claire Newbern; Marcelo H Fernandez-Viña; Bruce Herdman; Caroline C Johnson; Kendra M Viner
Journal:  J Urban Health       Date:  2015-04       Impact factor: 3.671

Review 4.  Impact of new therapeutics for hepatitis C virus infection in incarcerated populations.

Authors:  Anne S Spaulding; Arthur Y Kim; Amy Jo Harzke; Jean C Sullivan; Benjamin P Linas; Arthur Brewer; Jeff Dickert; Barbara H McGovern; Lara B Strick; Robert Trestman; Warren J Ferguson
Journal:  Top Antivir Med       Date:  2013 Feb-Mar

5.  Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations.

Authors:  Duncan Smith-Rohrberg Maru; Robert Douglas Bruce; Sanjay Basu; Frederick L Altice
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

6.  Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.

Authors:  Albert Do; Yash Mittal; AnnMarie Liapakis; Elizabeth Cohen; Hong Chau; Claudia Bertuccio; Dana Sapir; Jessica Wright; Carol Eggers; Kristine Drozd; Maria Ciarleglio; Yanhong Deng; Joseph K Lim
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

Review 7.  Hepatitis C in European prisons: a call for an evidence-informed response.

Authors:  Amber Arain; Geert Robaeys; Heino Stöver
Journal:  BMC Infect Dis       Date:  2014-09-19       Impact factor: 3.090

8.  Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons.

Authors:  Natasha K Martin; Matthew Hickman; Alec Miners; Sharon J Hutchinson; Avril Taylor; Peter Vickerman
Journal:  BMJ Open       Date:  2013-08-13       Impact factor: 2.692

9.  Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.

Authors:  Rob Bielen; Samya R Stumo; Rachel Halford; Klára Werling; Tatjana Reic; Heino Stöver; Geert Robaeys; Jeffrey V Lazarus
Journal:  Harm Reduct J       Date:  2018-05-11

10.  Integrating primary and secondary care to optimize hepatitis C treatment: development and evaluation of a multidisciplinary educational Masterclass series.

Authors:  Geoff McCombe; Bashayer Almaazmi; Walter Cullen; John S Lambert; Gordana Avramovic; Carol Murphy; Mairead O'Connor; Nicola Perry; Irina Ianache; Stefan Lazar; Tina McHugh; Julian Surey; Juan Macías; Peter Vickerman; Cristiana Oprea
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.